Reviewing Kaleido Biosciences (NASDAQ:KLDO) and Cybin (OTCMKTS:CYBN)

Cybin (OTCMKTS:CYBN) and Kaleido Biosciences (NASDAQ:KLDO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends and profitability.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Cybin and Kaleido Biosciences, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cybin	0	0	3	0	3.00
Kaleido Biosciences	0	0	0	0	0.00

Cybin presently has a consensus target price of $50.00, indicating a potential upside of 503.86%. Given Cybin’s stronger consensus rating and higher possible upside, equities analysts clearly believe Cybin is more favorable than Kaleido Biosciences.

Institutional and Insider Ownership

17.9% of Cybin shares are owned by institutional investors. Comparatively, 81.6% of Kaleido Biosciences shares are owned by institutional investors. 15.0% of Cybin shares are owned by insiders. Comparatively, 9.0% of Kaleido Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Volatility & Risk

Cybin has a beta of 0.64, indicating that its stock price is 36% less volatile than the S&P 500. Comparatively, Kaleido Biosciences has a beta of -0.06, indicating that its stock price is 106% less volatile than the S&P 500.

Profitability

This table compares Cybin and Kaleido Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cybin	N/A	-93.17%	-84.68%
Kaleido Biosciences	N/A	N/A	N/A

Valuation and Earnings

This table compares Cybin and Kaleido Biosciences”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cybin	N/A	N/A	-$35.93 million	($3.89)	-2.13
Kaleido Biosciences	$1.10 million	0.00	-$95.48 million	($2.24)	0.00

Cybin has higher earnings, but lower revenue than Kaleido Biosciences. Cybin is trading at a lower price-to-earnings ratio than Kaleido Biosciences, indicating that it is currently the more affordable of the two stocks.

About Cybin

Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation. It has also developed EMBARK, a psychological support model that integrates clinical approaches to promote supportive healing with psychedelic medicine. The company is headquartered in Toronto, Canada.

About Kaleido Biosciences

Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of multi drug resistant infection, chronic kidney disease, atherosclerotic cardiovascular disease, cardio-metabolic syndrome, immuno-oncology, and inflammatory bowel diseases. The company has collaboration agreements with Institute Gustave Roussy, Washington University, and Janssen. Kaleido Biosciences, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.